Safety and Effectiveness of the Omnipod 5 SmartAdjust 2.0 System in Individuals with Type 1 and Type 2 Diabetes
- Conditions
- Type 1 DiabetesType 2 DiabetesMetabolic and Endocrine - Diabetes
- Registration Number
- ACTRN12624000712505
- Lead Sponsor
- niversity of Otago, Christchurch.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 48
1. Age at time of consent 2-70 years
2. Diabetes diagnosis, based on Investigator's clinical judgement, and meets the following:
-Type 1 diabetes: 2-70 years old with HbA1c <11%. Diagnosed for at least 6 months for participants aged 2-<7 years or at least 1 year for participants aged 7-70 years.
Or
-Type 2 diabetes: 16-70 years old, diagnosed with T2D and on current insulin regimen for at least 3 months. Includes basal-bolus, pre-mix, or basal only users. For basal-bolus and premix users, must have HbA1c <12%. For basal only users must have HbA1c >=7.0% and <12%.
3. Living with a parent or guardian if < 16 years old
4. Currently using U-100 rapid-acting insulin analogs with insulin pump or basal-bolus, pre-mix, or basal only users suitable for conversion to pump therapy for at least 3 months prior to study start
5. Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novorapid, or their generic equivalents
6. Deemed appropriate for pump therapy per Investigator’s assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other
comorbidities
7. Stable doses over the preceding 4 weeks of other glucose lowering medications, as determined by Investigator, including within class dose equivalent medication
8. Stable doses over the preceding 4 weeks of weight loss medications that may affect glycemic control directly and/or indirectly, as determined by Investigator
9. Investigator has confidence that the participant and/or caregiver can safely operate all study devices and can adhere to the protocol
10. Willing to wear the system, including Pods, continuously throughout the study
11. If female of childbearing potential, willing and able to have pregnancy testing
1. Any medical condition, which in the opinion of the Investigator, would put the participant at an unacceptable safety risk
2. Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
3. Any planned surgery during the study which could be considered major in the opinion of the Investigator
4. Severe retinopathy based on retinal screening performed within the last 24 months
5. History of severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered consciousness, and
requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions
6. History of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness or infusion failure
7. Unable to tolerate adhesive tape or has any unresolved skin condition in the area of sensor or pump placement
8. Blood disorder or dyscrasia within 3 months prior to screening, including use of hydroxyurea, which in the Investigator’s opinion could interfere with determination of HbA1c
9. Plans to receive blood transfusion over the course of the study
10. Pregnant or lactating, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical
sterilization such as tubal ligation or hysterectomy, or vasectomized partner)
11. Participation in another clinical study using an investigational drug or device within 30-days or intends to participate in any other study during this study period
12. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator’s clinical judgment
13. Participant is an employee of Insulet, an Investigator or Investigator’s study team, or immediate family member of any of the aforementioned
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of time in hypoglycaemic range <3.9 mmol/L (<70 mg/dL)[Glycaemic metric as measured by the study CGM and assessed by diabetes type (T1D and T2D) At the end of Period 1 and Period 2 (optional) compared to Standard Therapy];Percentage of time in hyperglycaemic range >13.9 mmol/L (>250 mg/dL)[Glycaemic metric as measured by the study CGM and assessed by diabetes type (T1D and T2D) At the end of Period 1 and Period 2 (optional) compared to Standard Therapy]
- Secondary Outcome Measures
Name Time Method